A 70-year-old man developed severe periorbital edema secondary to imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ). Imatinib mesylate is a tyrosine kinase inhibitor with a high degree of specificity for the BCRABL, KIT, and platelet-derived growth factor receptor tyrosine kinases. It is thought that inhibition of platelet-derived growth factor receptor results in dis...

Disclosures: Alain Ravaud: Consultant/advisory role: Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer Schering; Christelle de la Fouchardière: None; Julien Asselineau: None; Jean-Pierre Delord: None; Christine Do Cao: None; Patricia Niccoli: None; Patrice Rodien: None; Marc Klein: None; Bogdan Catargi: None. The content of this article has been reviewed by independent peer reviewers to ensure th...

UTA ECKHARDT,1 ALICE SCHROEDER,1 BRUNO STIEGER,1 MATHIAS HÖCHLI,2 LUKAS LANDMANN,3 RONALD TYNES,4 PETER J. MEIER,1 AND BRUNO HAGENBUCH1 1Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, CH-8091 Zurich; 2Central Laboratory for Electron Microscopy, University of Zurich, CH-8028 Zurich; 3Department of Anatomy, University of Basel, CH-4000 Basel; and 4D...

Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases. Phase II and III clinical trials with the topical formulation of pimecrolimus (Elidel cream, Novartis) have shown that it is safe and effective for use in patients with atopic dermatitis (AD). ...

Affiliations: 1 Dana Farber Cancer Institute, Boston, MA, USA 2 Broad Institute, Cambridge, MA, USA 3 Novartis Institute for Biomedical Research, Cambridge, MA, USA 4 Department of Biological Engineering, MIT, Cambridge, MA, USA 5 Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA # Current address: Blueprint medicines, Cambridge, MA, USA *Corresponding author: Levi A Garra...

Foretelling the future is often the stuff of science fiction but for a team of scientists at the Novartis Institutes for BioMedical Research (NIBR), it’s their end goal. Led by Juliet Williams, Director of Oncology Pharmacology, and Bill Sellers, Global Head of Oncology, the team has developed a unique system to help predict how cancer drugs might fare well before they enter clinical testing: A...

The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581–1583 In the APPENDIX section of the article listed above, the affiliations for Makoto Sawaguchi and Nobuo Shirahashi are incorrectly listed as Shiga University of Medical Science and Osaka City Un...

1 Groningen Bioinformatics Centre, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Kerklaan 30, Haren, The Netherlands, 2 Department of Human Genetics, Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 3 Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America, 4 School of Pharmacy,...

By spying on cancer cells, Novartis researchers have a made a preliminary discovery that could potentially shape how targeted therapies are combined to treat patients. Currently doctors use the genomic profile of a patient’s tumor to select drugs that will hit the right target and shrink the cancer. Targeted therapy has prolonged many lives, but most cancers come back, and these drug-resistant ...

Institut de Génétique Moléculaire de Montpellier UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5; Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier cedex 5; Université Montpellier 1, 5 Bd Henry IV, 34967 Montpellier cedex 2, FRANCE. Institute of Genetics, The University of Nottingham, School of Biology, Queen’s Medical Center, Nottingham NG7 2UH, UK. Novartis Ins...